In non-low-risk DCIS of the breast, the addition of a TBB of radiation following postoperative WBI is associated with reduced local recurrence.
EPIK-B5 study evaluated alpelisib plus fulvestrant vs placebo for efficacy and safety in patients with PIK3CA-m HR+, HER2− advanced breast cancer who had progressed on a CDK4/6 inhibitor and an ...
Less-invasive lymph node procedures are noninferior to axillary lymph node dissection for 3-year recurrence outcomes in breast cancer patients.
Patients with HER2-positive, hormone receptor (HR)-positive metastatic breast cancer can be safely treated without chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback